Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam
Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)
DOI: 10.1128/aac.00897-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Salud Rodríguez-Pallares und 12 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hosp…. Hauptthemen laut MEDLINE: Ceftazidime, Cephalosporins, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg, Instituto de Salud Carlos III, Xunta de Galicia.
Abstract (Originalsprache)
The emergence of KPC variants associated with ceftazidime/avibactam resistance may also compromise the activity of other recently developed β-lactams, including cefiderocol and cefepime/taniborbactam. Xeruborbactam is a boronic acid β-lactamase inhibitor with potent activity against serine- and metallo-β-lactamases and is currently under clinical development in combination with cefiderocol. We evaluated the in vitro activity of cefiderocol/xeruborbactam against a panel of clinical Klebsiella pneumoniae isolates and isogenic Escherichia coli transformants (including both wild-type and porin-deficient backgrounds) producing KPC variants. Xeruborbactam and taniborbactam activities were compared using ceftazidime, cefepime, and cefiderocol as reporter substrates. Inhibitory activity was analyzed by determining the IC₅₀ values for both inhibitors against KPC variants. Most clinical isolates producing KPC variants showed increased MIC values and substantial cross-resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam. Cefiderocol/xeruborbactam retained potent activity against all clinical isolates, regardless of the KPC variant produced or the outer membrane permeability status. These findings were confirmed in wild-type and porin-deficient isogenic E. coli models, in which the combination of KPC variants and porin loss synergistically increased resistance to multiple β-lactams, while cefiderocol/xeruborbactam consistently restored susceptibility to wild-type levels. Comparative MIC analyses showed that xeruborbactam enhanced the activity of all β-lactam partners to a greater extent than taniborbactam. IC₅₀ determinations revealed a 17-fold to 73-fold greater inhibitory potency of xeruborbactam, which was maintained across structurally diverse KPC variants. Overall, cefiderocol/xeruborbactam exhibited potent activity against KPC-producing Enterobacterales, including isolates producing KPC variants associated with reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. Universidade da Co…
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
- Unidad Clínica de Microbiología, Hospital Universitario Reina Sofía, Córdoba, Spain.
ORCID-Profile: Salud Rodríguez-Pallares, Christophe Le Terrier, Tania Blanco-Martín, Cristina Elías-López, Lucía Sánchez-Peña, Carlos Molina-Cáceres, Gloria Pérez-Rodríguez, Lucía González-Pinto, Laurent Poirel, Germán Bou, Jorge Arca-Suárez
Förderung
- University of Fribourg
- Instituto de Salud Carlos III
- Xunta de Galicia
Zitieren
APA
Rodríguez-Pallares, S., Le Terrier, C., Blanco-Martín, T., Rilo-Antelo, R., Elías-López, C., Sánchez-Peña, L., Molina-Cáceres, C., Pérez-Rodríguez, G., González-Pinto, L., Martínez-Martínez, L., Poirel, L., Bou, G., & Arca-Suárez, J. (2026). Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.00897-26
Vancouver
Rodríguez-Pallares S, Le Terrier C, Blanco-Martín T, Rilo-Antelo R, Elías-López C, Sánchez-Peña L, et al. Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.00897-26
BibTeX
@article{RodrguezPallares2026,
author = {Rodríguez-Pallares, Salud and Le Terrier, Christophe and Blanco-Martín, Tania and Rilo-Antelo, Roberto and Elías-López, Cristina and Sánchez-Peña, Lucía and Molina-Cáceres, Carlos and Pérez-Rodríguez, Gloria and González-Pinto, Lucía and Martínez-Martínez, Luis and Poirel, Laurent and Bou, Germán and Arca-Suárez, Jorge},
title = {Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {11},
doi = {10.1128/aac.00897-26}
}
EUVIMED